VITAL Act of 2025

Bill Number

H.R. 3631

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Crime and Law Enforcement

Status

Introduced

Latest Action

2025-05-29: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Last Updated

2025-06-03T13:07:28Z

AI-Generated Summary

Purpose of the Legislation

The VITAL Act of 2025 aims to hold medical research companies and vaccine sponsors accountable for fraud in clinical vaccine trials by criminalizing deceptive practices and removing certain legal protections (like liability shields) when fraud is found. It focuses on ensuring transparency in data from vaccine trials, particularly during emergencies like pandemics, and allows injured individuals to pursue claims more easily if fraud occurred.

Key Provisions

• Criminal Penalty for Fraud (Section 2): Adds a new federal crime under U.S. criminal law (18 U.S.C. § 1041) for medical research companies or sponsors who make false statements or hide important data from U.S. government agencies about clinical vaccine trials. Penalties include fines, up to 5 years in prison, or both.
• Certification for Emergency Authorizations (Section 3): Requires companies to certify no fraud occurred when seeking emergency use authorization (EUA) for vaccines under the Federal Food, Drug, and Cosmetic Act (FD&C Act). EUA is a fast-track approval process for unapproved drugs or vaccines during public health emergencies.
• Revocation of Authorizations (Section 4): Allows the FDA to revoke an EUA if fraud in trial data is discovered.
• Exception to Right to Try Liability Limits (Section 5): Removes liability protections under the Right to Try Act (which lets terminally ill patients access experimental drugs without full FDA approval) if fraud is found in the drug's clinical trial data.
• Exception to Pandemic Liability Protections (Section 6): Modifies the Public Readiness and Emergency Preparedness (PREP) Act, which provides liability shields for makers of pandemic countermeasures (like vaccines). Fraud in trial data voids these protections, and damage awards in lawsuits cannot be reduced by other compensation received. Includes a hearing process before protections are removed.
• Changes to Vaccine Injury Compensation (Section 7): Updates the National Vaccine Injury Compensation Program (a no-fault system for vaccine-related injuries) to allow lawsuits against manufacturers if fraud is proven after a hearing. Claimants can seek program compensation and sue in court at the same time, with no reduction in damages from other sources. For COVID-19 vaccines (defined broadly to include SARS-CoV-2 variants with no end date), lawsuits can be filed anytime, without time limits.
• Hearing Process for Fraud Claims (Section 8): The Secretary of Health and Human Services (HHS) must provide a 30-day notice and hearing for companies accused of fraud. Companies must submit documents 5 days before the hearing, which can be in any format set by HHS. All testimony is published online. If a company doesn't respond, the fraud finding stands.

Significant Changes to Existing Law

• New Criminal Offense: Introduces a specific federal crime for vaccine trial fraud, which didn't exist before, targeting only medical research companies and sponsors.
• EUA and Revocation Rules: Adds fraud certification as a requirement for EUAs and grounds for revocation under the FD&C Act, tightening oversight during emergencies.
• Liability Exceptions: Pierces protections in the Right to Try Act, PREP Act, and Vaccine Injury Compensation Program by excluding fraud cases, shifting from broad immunity to conditional accountability. Previously, these laws offered strong shields to encourage rapid development of vaccines and treatments.
• COVID-19 Specifics: Removes statutes of limitations (time limits for filing claims) for COVID-19 vaccine injuries if fraud is involved, expanding access to justice indefinitely.
• Damage Award Rules: Prohibits reducing lawsuit damages based on other compensation, ensuring fuller recovery for plaintiffs in fraud cases.

Potential Impacts

• On Government Agencies: Increases workload for HHS and FDA in investigating fraud, conducting hearings, and revoking authorizations, potentially slowing emergency responses but improving data integrity.
• On Citizens: Enhances protections for vaccine trial participants and those injured by vaccines (especially COVID-19 ones) by enabling lawsuits and compensation without barriers, fostering greater trust in the process if fraud is deterred.
• On International Relations: Minimal direct impact, though it could influence global vaccine development collaborations by signaling stricter U.S. standards, possibly affecting how international sponsors interact with U.S. agencies.
• Broader Effects: May deter fraud but could raise costs and legal risks for vaccine development, potentially delaying future trials or increasing vaccine prices.

Main Stakeholders Affected

• Medical Research Companies and Vaccine Sponsors/Manufacturers: Face new criminal risks, loss of liability protections, and mandatory hearings, increasing operational and legal burdens.
• Government Agencies (HHS, FDA): Gain authority to enforce fraud rules but must handle more investigations and public disclosures.
• Citizens and Patients: Trial participants and vaccine recipients (particularly those harmed by COVID-19 vaccines) benefit from easier access to compensation and lawsuits.
• Healthcare Providers and Insurers: Indirectly affected through potential shifts in liability for experimental treatments during emergencies.

Notable Legal, Constitutional, or Political Implications

• Legal Implications: Strengthens enforcement against fraud under criminal and civil law, potentially leading to more litigation by creating exceptions to established immunity frameworks. The hearing process ensures due process (fair notice and opportunity to respond) before penalties, aligning with constitutional requirements under the Fifth Amendment.
• Constitutional Implications: Balances public health goals with individual rights by allowing civil actions, but the indefinite window for COVID-19 claims could challenge traditional statutes of limitations, raising questions about fairness to defendants.
• Political Implications: Addresses concerns over transparency in vaccine development (e.g., post-COVID skepticism) without altering core public health laws, but it may polarize debates on liability versus innovation incentives. The bill's focus on fraud could encourage accountability while avoiding broad deregulation of emergency powers.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Green, Mark E. [R-TN-7]

Recent Actions

• 2025-05-29: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-05-29: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-05-29: Introduced in House
• 2025-05-29: Introduced in House

Bill Versions

• Vaccines in Trial and Liability Act of 2025 — issued 2025-05-29 — PDF (9 pages)